{"organizations": [], "uuid": "a0a5087ce2d5732abb10456df3b3f6ce86979d8b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fibrocell-reports-on-interim-resul/brief-fibrocell-reports-on-interim-results-and-progress-of-phase-1-2-clinical-trial-of-fcx-007-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa-idUSASC0A304", "country": "US", "domain_rank": 408, "title": "BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.977, "site_type": "news", "published": "2018-05-21T19:18:00.000+03:00", "replies_count": 0, "uuid": "a0a5087ce2d5732abb10456df3b3f6ce86979d8b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fibrocell-reports-on-interim-resul/brief-fibrocell-reports-on-interim-results-and-progress-of-phase-1-2-clinical-trial-of-fcx-007-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa-idUSASC0A304", "ord_in_thread": 0, "title": "BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "fibrocell science inc", "sentiment": "neutral"}, {"name": "gene therapy for recessive dystrophic epidermolysis bullosa", "sentiment": "neutral"}, {"name": "epidermolysis bullosa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - Fibrocell Science Inc:\n* FIBROCELL REPORTS ON INTERIM RESULTS AND PROGRESS OF PHASE 1/2 CLINICAL TRIAL OF FCX-007 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA\n* FIBROCELL SCIENCE INC - FCX-007 WELL-TOLERATED UP TO 52 WEEKS POST-ADMINISTRATION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-21T19:18:00.000+03:00", "crawled": "2018-05-22T19:26:16.032+03:00", "highlightTitle": ""}